Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

Kates Max; Matoso Andres; Choi Woonyoung; Baras Alexander S.; Daniels Marcus J.; Lombardo Kara; Brant Aaron; Mikkilineni Nina; McConkey David J.; Kamat Ashish M.; Svatek Robert S.; Porten Sima P.; Meeks Joshua J.; Lerner Seth P.; Dinney Colin P.; Black Peter C.; McKiernan James M.; Anderson Chris; Drake Charles G.; Bivalacqua Trinity J.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

【24h】

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

机译：在非肌肉侵袭性膀胱癌中对膀胱内BCG的适应性免疫抗性：对预期BCG无响应试验的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To characterize immune cell expression among patients with non-muscle invasive bladder cancer (NMIBC) treated with Bacillus Calmette-Guerin (BCG).

机译：目的：用芽孢杆菌（BCG）处理非肌肉侵袭性膀胱癌（NMIBC）患者的免疫细胞表达。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2020年第4期|共10页
作者
Kates Max; Matoso Andres; Choi Woonyoung; Baras Alexander S.; Daniels Marcus J.; Lombardo Kara; Brant Aaron; Mikkilineni Nina; McConkey David J.; Kamat Ashish M.; Svatek Robert S.; Porten Sima P.; Meeks Joshua J.; Lerner Seth P.; Dinney Colin P.; Black Peter C.; McKiernan James M.; Anderson Chris; Drake Charles G.; Bivalacqua Trinity J.;
展开▼
作者单位

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

Columbia Univ Med Ctr New York NY USA;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

MD Anderson Canc Ctr Houston TX USA;

Univ Texas Hlth Sci Ctr San Antonio San Antonio TX 78229 USA;

Univ Calif San Francisco San Francisco CA 94143 USA;

Northwestern Univ Sch Med Chicago IL USA;

Baylor Univ Sch Med Houston TX 77030 USA;

Columbia Univ Med Ctr New York NY USA;

Vancouver Prostate Ctr Vancouver BC Canada;

Vancouver Prostate Ctr Vancouver BC Canada;

Vancouver Prostate Ctr Vancouver BC Canada;

Vancouver Prostate Ctr Vancouver BC Canada;

Johns Hopkins Sch Med James Buchanan Brady Urol Inst Baltimore MD 21287 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials [J] . Kates Max, Matoso Andres, Choi Woonyoung, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第4期

机译：在非肌肉侵袭性膀胱癌中对膀胱内BCG的适应性免疫抗性：对预期BCG无响应试验的影响
2. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guerin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [J] . Cyrill A. Rentsch, Piet Bosshard, Gregoire Mayor, Oncoimmunology. . 2020,第1期

机译：I阶段的结果开放标签临床试验SAKK 06/14评估VPM1002BC的脑内滴注的安全性，重组分枝杆菌秃鹰植物蛋白（BCG），在非肌肉侵袭性膀胱癌的患者中，以前的常规BCG治疗失败
3. Molecular mechanisms and novel therapeutic strategies of BCG-unresponsive non-muscle invasive bladder cancer: Emerging immunotherapy has become a new choice? [J] . Xin-Ming Hu, Lei Xu, Jun Gu, 海南医科大学学报（英文版） . 2020,第014期

机译：BCG无反应性非肌肉浸润性膀胱癌的分子机制和新的治疗策略：新兴的免疫治疗已成为新的选择？
4. PROSPECTIVE TRIAL OF 5-AZACITIDINE IN DOGS WITH NATURALLY-OCCURRING INVASIVE URINARY BLADDER CANCER, AN EPIGENETIC APPROACH TO CANCER THERAPY. [C] . Noah Hahn, Deborah Knapp, Michael Childress, Annual Conference of the Veterinary Cancer Society . 2009

机译：患有自然侵袭性膀胱癌的5-氮杂氨酸的前瞻性试验，癌症治疗的表观遗传方法。
5. Understanding treatment-related symptoms, symptom management techniques, and symptom management self-efficacy in a sample of non-muscle invasive bladder cancer patients [D] . Hinojosa-Lindsey, Marilyn 2010

机译：了解非肌肉浸润性膀胱癌患者样本中与治疗相关的症状，症状管理技术和症状管理自我效能
6. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC a recombinant mycobacterium Bacillus Calmette Guérin (BCG) in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [O] . Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, 2020

机译：I期开放标签临床试验SAKK 06/14的结果评估了非肌肉浸润性膀胱癌和以前常规BCG治疗失败的患者中VPM1002BC重组分枝杆菌芽孢杆菌Guérin（BCG）膀胱内滴注的安全性
7. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy [O] . Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, 2020

机译：I阶段开放标签临床试验SAKK 06/14评估VPM1002BC脑滴注的安全性，该重组分枝杆菌BacultusBudetteguérin（BCG），在非肌肉侵袭性膀胱癌患者中，以前的常规BCG治疗失败

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials

摘要

著录项

相似文献

相关主题

期刊订阅